The Power of Combination Therapies: One Patient’s Road to Remission
By Pooja H. Rambhia, MD Candidate, Case Western Reserve University | 28 February 2017 In Science, Treatment
Metastatic melanoma can be a devastating diagnosis to receive. Just hearing the word cancer for most is terrifying. While the fear is understandable, today new targeted therapies and immunotherapies are delivering new hope for many.
Melanoma 2016 — the Year in Review
By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 20 January 2017 In News
In the nearly 10 years since MRA’s founding in 2007, there has been extraordinary progress for melanoma. With 11 new treatments approved since 2011, it began to feel like frequent new drug approvals was the current norm.
Understanding Neoantigens: A Critical Target for Improving Immunotherapy
By Kristen Mueller, Ph.D., MRA Scientific Program Director | 20 January 2017
The approval of eleven new therapies for melanoma since 2011 has led to dramatic changes in how doctors treat melanoma and even more importantly, has led to better outcomes for many patients. Chief among the new therapies are those that target the immune system.
Melanoma Immunotherapy and Precision Medicine — a Medical Student’s Perspective
By Pooja H. Rambhia, MD Candidate, Case Western Reserve University | 20 January 2017 In Science
Malignant melanoma research has provided the perfect opportunity to explore the intersection of immunotherapy and precision medicine, which has greatly transformed melanoma therapeutics in the last decade.
Tara's Story
By Pamela Goldsmith, MRA Director of Communications | 20 January 2017 In Melanoma Stories
To say that Tara Miller inspired mixed emotions is to begin to understand her life. The strong-willed survivor, who lost her battle to melanoma in 2014, reflected the contradictions that define an indomitable will to live.
Parallels between Disease States
By Michael Kaplan, MRA President & CEO | 30 November 2016 In Science
Six months ago I was offered the opportunity to serve as President & CEO of MRA and in July, I officially began. For the past 24 years, I’ve worked in the HIV field and am struck by the many parallels that exist between my past work and melanoma.
Uncommon Immunotherapy Side Effects
By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 30 November 2016
A recent report in the prestigious New England Journal of Medicine (NEJM), has spawned reports like this one, regarding the risk of death in patients treated with combination checkpoint treatments. The first author of the NEJM story is MRA-funded investigator, Doug Johnson at Vanderbilt.
Championing Collaboration
By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 30 November 2016
Some have the impression that cancer researchers, whether in academia or in industry, toil away in isolation. While there are certainly scientists who work best on their own, collaboration among researchers has become increasingly common, with a goal of achieving the most promising results in the shortest time frame.
MRA Funded Melanoma Researchers Led Discussions at 2016 Annual Meeting of the Society for Immunotherapy of Cancer
By Pamela Goldsmith, MRA Director of Communications | 30 November 2016
MRA Director of Communications Melanoma Research Alliance (MRA) investigators and other melanoma researchers had a significant presence at this year’s annual meeting of the Society for Immunotherapy of Cancer (SITC) held in National Harbor, Maryland. A key forum for scientific exchange and enlightenment in the cancer immunotherapy field, the conference...
Tag Cloud
Adjuvant Therapy Advocacy ASCO Awareness Board Members BRAF Cancer Combination Therapy Detection FDA Grants Immunotherapy Melanoma microbiome MRA Partners Patient Forum Patient Stories Patient-Centric Care Patients Pediatric Melanoma Prevention Research Science Social Media Targeted Therapy Teens Treatment Wendy Selig Young Investigators Young People